(redirected from Fabry's disease)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to Fabry's disease: Pompe disease
References in periodicals archive ?
Physiological characterization of neuropathy in Fabry's disease.
Fabry's disease is a fat-storage disorder, which impairs circulation, leading to kidney failure, heart attacks and strokes.
Key Words: conduction defects, Fabry's disease, first-degree atrio-ventricular block, restrictive physiology, right bundle branch block
Sinai Medical Center in New York City infused the missing enzyme into 29 adults with Fabry's disease.
Most importantly, the report provides valuable insights on the pipeline products within the global Fabry's Disease Therapeutics sector.
Safety and efficacy of recombinant human a-galactosidase A-replacement therapy in Fabry's disease.
The report provides information on the key drivers and challenges of the Fabry's Disease Therapeutics market.
5,962,313 to Avigen and Johns Hopkins University (JHU) covering recombinant adeno-associated virus (AAV) vectors carrying lysosomal enzyme genes for the treatment of lysosomal storage diseases, including Gaucher's, Tay-Sachs, and Fabry's disease.
Neuraltus has three clinical-stage programs in its development pipeline, including potential treatments for Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease), Parkinson's disease and dyskinesias associated with the treatment of Parkinson's disease, Alzheimer's disease, and multiple sclerosis, as well as lysosomal storage disorders such as Fabry's disease and Gaucher's disease.
Safety and efficacy of recombinant human [alpha]-galactosidase A replacement therapy in Fabry's disease.
This molecule may be effective in the treatment of Fabry's disease, a multi-systemic, lipid storage disorder caused by a deficiency of this lysosomal enzyme.